Vilpower Tablets (Vildagliptin)

• Composition :
  Each uncoated tablet contains vildagliptin 50 mg.
• Indications :
  As an adjunct to diet and exercise to improve glycaemic control in patients with type-II diabetes mellitus.
• Pharmacodynamics :
  Vildagliptin is a dipeptidyl peptidase-4 inhibitor. By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion. The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.
• Dosage and administration :
  The usual dose is 50 mg tablet twice daily, one tabletin the morning andone tablet in the evening. Can be given with or without food.
• Contraindications :
  Hypersensitivity to the active substance or to any other excipients of the formulation.
• Precautions and warnings :
  Not recommended in hepatic impairment, moderate or severe renal impairment. Not recommended in paediatric patients.
• Use in pregnancy, lactation & pediatrics :
  There are no adequate studies of vildagliptin in these populations. Vildagliptin should not be used during pregnancy or lactation. Not recommended for use in children under 18 years of age
• Drug interactions :
  Vildagliptin has a low potential for drug interactions. No clinically relevant interactions with oral antidiabetic drugs (glibenclamide, pioglitazone, metformin), amlodipine, digoxin, ramipril, simvastatin, valsartan or warfarin were observed after co-administration with vildagliptin.
• Adverse reactions :
  Most common adverse reactions are headache, dizziness, constipation, peripheral oedema, hypoglycaemia.
• Therapy Area :
  Anti-Diabetic agents